BiomX Inc.

Hello, and welcome to the Biomics first quarter 2024 financial results. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to CFO Avi Gabay. Please go ahead, Avi.

Thank you and welcome to the Biomix first quarter 2024 financial results and corporate update conference call. The press release became available just after 6.30 a.m. Eastern time today and can be found on our website at www.biomix.com. A replay of this call will also be available on the investor section of our website. Before we begin, I'd like to review the safe harbor provision. All statements on this call that are not factual historical statement may be deemed forward-looking statements. For instance, we're using forward-looking statements when we discuss in the conference call the sufficiency of the combined company's financing, potential stockholder approval of certain matters related to the securities issued and related matters in connection with the adaptive phase therapeutics or APT merger, potential market opportunities, the ability to drive value for stockholders, the design, recruitment, aim, expected timing, and interim and final results of our preclinical and clinical trial, the regulatory process and discussion with the FDA, the potential benefits and commercial opportunities of our product candidate, and the potential safety and efficacy of BX004 and BX211. In addition, past and current preclinical and clinical results, as well as compassionate use, are not indicative and do not guarantee future success of our clinical trials. Except as required by law, we do not undertake to update forward-looking statements. The full Safe Harbor provision, including risks that could cause actual results to differ from these forward-looking statements, are outlined in today's press release, which, as noted earlier, is on our website. Joining me to call this morning is Jonathan Solomon, Chief Executive Officer of Biomics. With that, I'll turn the call over to Jonathan.

Good morning, everyone. For the first time, Biomix is reporting results for a combined entity following our merger with APT in March, and Avi will elaborate more on this. Overall, the first quarter of 2024 was nothing less than transformational for Biomix. The company has now entered into a new era. With the merger with APT in March, we have expanded our mid-clinical stage programs, which we believe constitute the leading phage-related pipeline in the industry. We are now advancing diverse approaches focused on developing natural phage crocs and personalized phage treatments. With the recent merger, we've added a second Phase II product candidate, BX211, for the treatment of diabetic foot osteomyelitis, or DFO. And I'll review our progress shortly. BX004, our most advanced mid-clinical stage candidate, has already shown what we believe are promising clinical results supporting the potential of phage therapy to treat harmful bacteria underlying serious chronic infections in cystic fibrosis or CF patients. The broadening of our pipeline, the diversity of our approaches, and the data we've seen to date are all key in reducing risk inherent in biotech developments. Concurrently with the merger with APT, we raised $50 million of gross proceeds in a private placement led by affiliates of Deerfield Management and the AMR Fund with the participation of additional existing and new investors including the Cystic Fibrosis Foundation Orbimed, and Nathanael Capital Management. These important and accredited life sciences investors provide further validation for the potential of phage therapy as a new therapeutic modality and the strength of our lead candidates, each having the potential to advance the standard of care in their prospective disease area. Including net proceeds from the financing in our existing capital, Biomics now expects to have sufficient funding to reach multiple important clinical milestones through 2025, including expected data readouts for our lead candidates, BX211 and BX004, in the first quarter of 2025 and the third quarter of 2025, respectively. We believe these Phase II data readouts could potentially drive significant value for our stockholders. We are thrilled with the continuing progress of both of our Phase II programs. On our last earnings calls, I had the opportunity to take a deep dive into BX211 as part of the merger with APT. As a reminder, BX211 is a personalized phase treatment being evaluated in the randomized, double-blinded, placebo-controlled, multi-center phase 2 trial for subjects with DFO associated with Staphylococcus aureus. This is an area of high unmet need. Each year, there is a staggering number of approximately 160,000 lower limb amputations in diabetic patients in the U.S. alone, 85% of which are caused by DFO, according to the Centers for Disease Control and the literature. We believe that phage-based therapeutic approaches have the potential to greatly improve treatment outcomes in DFO. Reports in the scientific literature of compassionate use with phage therapy have shown that 11 of 12 cases resulted in positive outcomes of wound healing and avoiding amputation. Finding from these cases played an important role in the design of the ongoing phase two of BX211. With the target enrollment of 45 patients, the trial has already surpassed 70% of this target. We remain on track to report on the week 13 treatment results in the first quarter of 2025. We are also excited by the progress of BX004, our other lead mid-clinical stage candidate. BX004 is a fixed multi-stage cocktail for the treatment of CF patients with chronic pulmonary infections caused by pseudomonas arginosa, a main contributor to the mobility and mortality in these patients. In January this year, we were granted orphan drug designation by the FDA for BX004. More recently, in April, we presented positive safety and efficacy results from Part 2 of a Phase 1 B2A trial of BX004 at the European Society of Clinical Microbiology and Infectious Disease, or ESCMID, Global Congress. In fact, our presentation was selected as a top poster, ranking it among the top first-second percentile of top-rated abstracts in the category submitted and accepted at the Congress. We believe that the data for BX004 are the most promising advanced findings published to date for phage therapy for the treatment of chronic pulmonary infections in CF patients. We've shown with BX004 both conversion to sputum culture-negative pseudomonas organosa in 14.3% of patients and demonstrated signals of improved pulmonary function after only 10 days of treatment. Both findings in contrast to results in placebo. Under a Phase IIb trial, we now plan to treat for a much longer treatment duration of two months, which we believe has the potential to demonstrate a more pronounced effect on both micrological and lung functional readouts. As previously reported, by mid-2024, we anticipate holding a Type C meeting with the FDA to discuss our clinical development plans for BX004. Pending alignment with the FDA and completion of the remaining CMC work, our plan is to submit a Phase IIb study protocol to all relevant regulatory authorities and initiate the study by the end of this year. As already noted, we estimate releasing top line results on the study in the third quarter of 2025. We are thrilled to have what we believe is the broadest and most advanced phage pipeline with promising data already reported and key readouts in phase two studies in both our lead programs in 2025. On this final note, I'll now pass it over to Avi to review our first quarter 2024 financial results. Avi.

Thank you, Jonathan. As a reminder, the financial information is available in the press release we issued earlier today and also in more detail in our Form 10-Q that was filed yesterday. I will walk you through some of our brief highlights. As of March 31st, 2024, cash balance and short-term deposit were $44.1 million compared to $30.3 million as of March 31st, 2023. The increase was primarily due to the private placement, which was partially offset by net cash using operating activities and the repayment of the debt facility in March 2024. The company estimates its cash, cash equivalent, and short-term deposits are sufficient to fund its operation throughout the fourth quarter of 2025. In the first quarter of 2024, research and development expenses net totaled $4.1 million compared to $4.6 million in the first quarter of 2023. Mainly because of less expenses due to the end of the CF clinical trial and was partially offset by lower grants payment from the Israeli Innovation Authority and R&D expenses related to the APT that were incurred after the merger. General and administrative expenses were $2.7 million for the first quarter of 2024. compared to $1.6 million for the same period in 2023. The increase was primarily due to expenses related to the merger with APT and the concurrent private placement. Net loss for the first quarter of 2024 was $17.3 million, compared to $6.4 million for the first quarter of 2023. The increase is mainly due to change to fair value of private placement warrants that were issued in this quarter. Net cash used in operating activity for the first quarter of 2024 was $11.4 million compared to $5 million for the same period in 2023. On March 15, 2024, we closed the merger with APT, concurred with an investment of $15 million. We would like to emphasize that although after the financing, we believe we will have sufficient cash, cash equivalent, and short-term deposit to fund our current operating plan at least 12 months, Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. This is mainly due to the potential risk of our stockholders not approving the conversion of the convertible preferred stock that was issued as part of the merger with APT and the concurrent investment. And now I'll turn the call back over to Jonathan for his closing remarks. Jonathan.

We've accomplished a lot so far in 2024, and we're looking forward to the continuing substantial momentum at Biomics through this year and into 2025. With recent development, Biomics has set itself apart as a leader in developing phage-based therapeutics. The merger and $50 million investment from top institutional healthcare investors allowed us to expand our pipeline and position us to achieve key data readouts next year. By advancing our BX004 and BX211 clinical programs, our company is poised to build significant value for our stockholders. As at the recent ESCMID Congress, our team will continue to seek important opportunities to present in peer-reviewed forums. Based on our recent financing, we believe the company has sufficient cash runway to reach additional important clinical milestones as we advance our phage candidates addressing serious chronic infections. Indeed, it is a new era for bionics.

Thank you. We'll now be conducting a question and answer session. If you'd like to be placed into question queue, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. One moment, please, while we poll for questions. And once again, that's star 1 to be placed into question queue. Our first question today is coming from Joe Pangenis from HC Wainwright. Your line is now live.

Hey guys, good morning, good afternoon. Thanks for taking the question. So two questions, Jonathan. For the upcoming Phase II B and CF, I was just curious, I mean, even since your year-end call or what have you, as you've been talking to, you know, additional physicians and KOLs, has there been any additional evolution in your thinking about the design of the study, inclusion criteria, et cetera, going into your Type C meeting? And then the second question is, how are your integration efforts going with regard to the varying manufacturing facilities? Thanks a lot.

Good morning, Joe, and thanks for the great questions as always. So first on the CF study, so, you know, we spent quite a lot of time analyzing the data and working hand-in-hand with the CF Foundation. So I think we have a good handle on the design of the FAVES-2B, trying to address some of the questions that we've discussed and trying, obviously, you know, to increase the percentage of patients that experience conversion and get, you know, even clearer signals on both microbiology as well as clinical endpoints. So I think that has matured. Again, I think we're waiting for the FDA meeting, and we'll see kind of where the feedback is. If all is according to plan, then I think we're locked and loaded to initiate the study at the end of the year. So, so far, I think, again, there was a lot of work up front, so I think we feel good about it. The integration, so I'm now in sunny BC. By the way, the weather is gorgeous. And, you know, it's definitely not a simple task to integrate these two companies. But I think as time goes, the rationale kind of plays out, right? So I do think it plays into APT's strength in terms of the manufacturing capability, the access to, you know, compassionate cases, the knowledge, access to governmental agencies. So I think all those are strengths that, quite frankly, biomics lacked. So I think it's proceeding well. Like every integration, you know, it's not simple. But, you know, there's been a lot of effort. The teams have been traveling quite extensively. And now I think we feel that the situation is sort of stabilized and there's very clear work plans, budgets approved, and we're ready to go. So crossing our fingers to kind of continue the momentum and, again, generate more value.

Appreciate the comments. Thanks, Jonathan.

Pleasure as always.

Thank you. Next question is coming from Yeo Jin from Lade Long Company. Your line is now live.

Good afternoon, and thanks for taking the questions, and congratulations, Jonathan. I've got two questions here. First one is a follow-up with Joe's question, which is that in terms of the Phase II study you're proposing, would that be potentially adding an extension part after the trial is done so a patient can get a longer treatment, and that's one, and then I have a follow-up.

Okay, so I think, you know, the phase two is already quite a long duration, right? We're going for two months, and we will follow up the patients and think about whether we extend if we're seeing conversion. So I think these are items that we're discussing. You know, I think a lot depends on feedback from MTA. There will be a longer follow-up for sure. I do think there's a chance to also explore extending it. Definitely, I think we'll want to extend to some extent in the patients that have experienced conversion, kind of see how long can we keep the, you know, the bug at bay, right? So I think that would be very dramatic. So it's definitely one of the items that we're discussing. And, and Yale, I believe you had another question.

Yes, I do. And this is a little bit more fundamental questions here. As we know that the virus, I'm sorry, the phage has the lytic and the lipogenic phase. So how would you ensure that all your products are retained as in the lytic state and that that is the functional state of the phage for killing the bacteria? And thanks.

Yeah, yeah, it's a good question. And, you know, viruses are, phage are viruses, right? So I do think it's a valid analogy. You know, by the way, the big conference is like viruses and microbes, the phage conference. I think, to your point, the FDA has been very clear on not wanting to advance forward phage, which are lysogenic, right? And the way to address it is actually by making sure that all the phage that we deploy, whether in the personalized approach, such as the DSO study, or in the cocktail, actually don't have any lysogeny gene. So we sequence everything. Again, these are quite a few genes, so it's not that a spontaneous single mutation will introduce lysogeny, right? It's not that we knocked off lysogeny with a single mutation. There's no lysogeny genes whatsoever. So, you know, the probability of a phage kind of acquiring or developing lysogeny genes is measurable. So that's the approach. Again, sequencing, making sure that the phage don't have those capabilities, and it's all part of the battery of tests, you know, such as generalized transduction and other attributes that the FDA has been very clear on what kind of characteristics they want to see and what characteristics they don't want to see in a phage product undergoing development.

Okay, great. That's very helpful for investors. And again, congrats on all the progress and look forward to talking to you next time.

Thanks, Yale, for the kind words.

Thank you. Next question today is coming from Michael Higgins from Lattenburg-Thompson. Your line is now live.

Hi, guys. Good morning. This is Farhana on behalf of Michael. Congrats on your continued progress. Two questions from us. The first on BX004. Could you confirm with us that aligning with the EMA is also in 2024? And the second question is on BX211. Any gating factors to completing enrollment in the Phase II DFO study?

Good morning and good questions. Just to make sure regarding the first question, you mean like the European compliance of the X004? Yes. Got it. Okay. So all good question. Again, you know, BX004, going after CF, orphan indication, you know, as we've talked through the years, right, recruitment is not trivial. We struggled a bit in the part one, and I think then we gained a lot of momentum in the part two. But that already was a global study, right? So already in the part, In the part two of the phase 2A, we had U.S. sites, European sites, as well as Israeli sites. So that's going to continue. I think we're looking at much more sites in the second study of the phase 2B. Definitely Europe is going to be key. We've experienced, I think, very good recruitment in the U.S., and we'll definitely continue that. So that's in the works and part of the work plan and the timelines that we've presented. BX211, so enrollment is going well as reported this morning. 70% of patients have been enrolled. Again, I think these studies are not trivial. It's a complex indication. We want to verify that the patients have the bacteria. We're deploying the phage banks. That means that we ship basically phage to our sites. We optimize the best phage for that patient. We ship it back, and that's the treatment that the patient gets. So we have seen challenges. Again, there's a lot of experience in the system by now with these studies. So, you know, I think we've learned a lot. We will put some effort even to try to, if we can, improve recruitment rates. But, you know, so far it's going well and it's meeting our expectations. But, you know, clinical studies are always difficult. So let's just hope it continues the way it has.

Thank you.

Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over for any further or closing comments.

Thank you again, everyone, for joining us this morning. We look forward to providing you with updates throughout the year, and have a great day. Thank you.

Thank you. That does conclude today's teleconference and webcast. You may disconnect or line up this time, and have a wonderful day. We thank you for your participation today.